Iranian
Biomedical Journal
Volume 24, Issue 4 (7-2020)
IBJ 2020, 24(4): 206-213 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zohouri M, Ghaderi A. The Significance of Biobanking in the Sustainability of Biomedical Research: A Review. IBJ 2020; 24 (4) :206-213
URL: http://ibj.pasteur.ac.ir/article-1-3045-en.html
URL: http://ibj.pasteur.ac.ir/article-1-3045-en.html
Abstract:
Biobank, defined as a functional unit for facilitating and improving research by storing biospecimen and their accompanying data, is a key resource for advancement in life science. The history of biobanking goes back to the time of archiving pathology samples. Nowadays, biobanks have considerably improved and are classified into two categories: diseased-oriented and population-based biobanks. UK biobank as a population-based biobank with about half a million samples, Biobank Graz as one of the largest biobanks in terms of sample size, and The International Agency for Research on Cancer biobank as a specialized the World Health Organization cancer agency are few examples of successful biobanks worldwide. The present review provides a history of biobanking, and after presenting different biobanks, we discuss in detail the challenges in the field of biobanking and its future, as well. In the end, ICR biobank, as the first cancer biobank in Iran established in 1998, is thoroughly described.
Type of Study: Review Article |
Subject:
Related Fields
References
1. De Souza YG, Greenspan JS. Biobanking past, present and future: responsibilities and benefits. AIDS 2013; 27(3): 303-312. [DOI:10.1097/QAD.0b013e32835c1244]
2. Morente MM, Fernández PL, de Alava E. Biobanking: old activity or young discipline? Proceedings of the Seminars in diagnostic pathology 2008; 25(4): 317-322. [DOI:10.1053/j.semdp.2008.07.007]
3. Organisation for Economic Co-operation and Development (OECD). Biological Resource Centres: Underpinning the Future of Life Sciences and Biotechnology. Paris: OECD, 2001.
4. Asslaber M, Zatloukal K. Biobanks: transnational, European and global networks. Briefings in functional genomics and proteomics 2007; 6(3): 193-201. [DOI:10.1093/bfgp/elm023]
5. Kinkorová J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation: Overview. The EPMA journal 2015; 7: 4. [DOI:10.1186/s13167-016-0053-7]
6. Park A. 10 Ideas Changing the World Right Now. TIME. March 12. 2009.
7. Massett HA, Atkinson NL, Weber D, Myles R, Ryan C, Grady M, Compton C. Assessing the need for a standardized cancer HUman Biobank (caHUB): findings from a national survey with cancer researchers. Journal of the national cancer institute monographs 2011; 2011(42): 8-15. [DOI:10.1093/jncimonographs/lgr007]
8. Watson RWG, Kay EW, Smith DJNRC. Integrating biobanks: addressing the practical and ethical issues to deliver a valuable tool for cancer research. Nature review cancer 2010; 10(9): 646-651. [DOI:10.1038/nrc2913]
9. Moore HM, Compton CC, Lim MD, Vaught J, Christiansen KN, Alpe J. 2009 Biospecimen research network symposium: advancing cancer research through biospecimen science. Cancer research 2009; 69(17): 6770-6772. [DOI:10.1158/0008-5472.CAN-09-1795]
10. Riegman PH, Morente MM, Betsou F, De Blasio P, Geary P. Biobanking for better healthcare. Molecular oncology 2008; 2(3): 213-222. [DOI:10.1016/j.molonc.2008.07.004]
11. Woolf SH. The meaning of translational research and why it matters. JAMA 2008; 299(2): 211-213. [DOI:10.1001/jama.2007.26]
12. Eiseman E, Haga SB. Handbook of Human Tissue Sources. A National Resource of Human Tissue Samples. Handbook of Human Tissue Sources: A National Resource of Human Tissue Samples, 1999, Santa Monica: RAND.
13. Rahbari R, Sheahan T, Modes V, Collier P, Macfarlane C, Badge RM. A novel L1 retrotransposon marker for HeLa cell line identification. Biotechniques 2009; 46(4): 277-284. [DOI:10.2144/000113089]
14. Jones HW Jr. Record of the first physician to see Henrietta Lacks at the Johns Hopkins Hospital: history of the beginning of the HeLa cell line. American journal of obstetrics and gynecology 1997; 176(6): s227-s228. [DOI:10.1016/S0002-9378(97)70379-X]
15. Smith V. Wonder woman: The Life, Death, and Life after Death of Henrietta Lacks, Unwitting Heroine of Modern Medical Science. Baltimore City Paper. 2002.
16. Batts DW. Cancer cells killed Henrietta Lacks - then made her immortal. Reterieved from: https://www. pilotonline.com/news/health/article_17bd351a-f606-54fb-a499-b6a84cb3a286.html.
17. Rebulla P, Lecchi L, Giovanelli S, Butti B, Salvaterra E. Biobanking in the year 2007. Transfusion medicine and homotherapy 2007; 34(4): 286-292. [DOI:10.1159/000103922]
18. Assabler M, Zatloukal K. Biobanks: transnational, European and global network. Briefings in functional genomics and proteomics 2007; 6(3): 193-201. [DOI:10.1093/bfgp/elm023]
19. Swede H, Stone CL, Norwood AR. National population-based biobanks for genetic research. Genetics in medicine 2007; 9(3): 141-149. [DOI:10.1097/GIM.0b013e3180330039]
20. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nature reviews cancer 2007; 7(7): 545-553. [DOI:10.1038/nrc2173]
21. Luo J, Guo XR, Tang XJ, Sun XY, Yang ZS, Zhang Y, Dai LJ, Warnock GL. Intravital biobank and personalized cancer therapy: The correlation with omics. International journal of cancer 2014; 135(7): 1511-1516. [DOI:10.1002/ijc.28632]
22. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nature reviews clinical oncology 2011; 8(3): 184-187. [DOI:10.1038/nrclinonc.2010.227]
23. WHO IAfRoC. Common Minimum Technical Standards and Protocols for Biological Resource Centres Dedicated to Cancer Research. France: International Agency for Research on Cancer, 2007.
24. Lu D, Zhou X, Yao L, Liu C, Jin F, Wu Y. Clinical implications of the interleukin 27 serum level in breast cancer. Journal of investigative medicine 2014; 62(3): 627-631. [DOI:10.2310/JIM.0000000000000046]
25. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nature immunology 2005; 6(12): 1219-1227. [DOI:10.1038/ni1265]
26. de Lafaille MAC, Lafaille JJJI. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009; 30(5): 626-635. [DOI:10.1016/j.immuni.2009.05.002]
27. Bahcall OG. UK Biobank-a new era in genomic medicine. Nature reviews genetics 2018; 19(12): 737. [DOI:10.1038/s41576-018-0065-3]
28. Chen Z, Chen J, Collins R, Guo Y, Peto R, Wu F, Li L. China Kadoorie Biobank (CKB) collaborative group. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. International journal of epidemiology 2011; 40(6): 1652-1666. [DOI:10.1093/ije/dyr120]
29. Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T, Tamakoshi A, Yamagata Z, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y, Biobank Japan Cooperative Hospital Group, Kubo M. Overview of the BioBank Japan Project: study design and profile. Journal of epidemiology 2017; 27(3 Supplement): S2-S8. [DOI:10.1016/j.je.2016.12.005]
30. Huppertz B, Bayer M, Macheiner T, Sargsyan K. Biobank Graz: the hub for innovative biomedical research. Open journal of bioresources 2016; DOI: 10.5334/ojb.20. [DOI:10.5334/ojb.20]
31. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie S, Allen N, Donnelly P, Marchini J. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018; 562(7726): 203-209. [DOI:10.1038/s41586-018-0579-z]
32. Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daigo Y, Nakamura Y, Kamatani N. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nature genetics 2010; 42(3): 210-215. [DOI:10.1038/ng.531]
33. Vaught J, Rogers J, Myers K, Lim MD, Lockhart N, Moore H, Sawyer S, Furman JL, Compton C. An NCI perspective on creating sustainable biospecimen resources. Journal of the national cancer institute monographs 2011; 2011(42): 1-7. [DOI:10.1093/jncimonographs/lgr006]
34. Chalmers D, Nicol D, Kaye J, Bell J, Campbell AV, Ho CW, Kato K, Minari J, Ho CH, Mitchell C, Molnár-Gábor F, Otlowski M, Thiel D, Fullerton SM, Whitton T. Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era. BMC medical ethics 2016; 17(1): 39. [DOI:10.1186/s12910-016-0124-2]
35. Rothstein MA. Expanding the ethical analysis of biobanks. The journal of law, medicine and ethics 2005; 33(1): 89-101. [DOI:10.1111/j.1748-720X.2005.tb00213.x]
36. Clayton EW. Ethical, legal, and social implications of genomic medicine. The new England journal of medicine 2003; 349(6): 562-569. [DOI:10.1056/NEJMra012577]
37. OECD. Guidelines on Human Biobanks and Genetic Research Databases. 2009.
38. Watson PH, Nussbeck SY, Carter C, O'Donoghue S, Cheah S, Matzke LA, Barnes RO, Bartlett J, Carpenter J, Grizzle WEJB, Johnston RN, Mes-Masson AM, Murphy L, Sexton K, Shepherd L, Simeon-Dubach D, Zeps N, Schacter B. A framework for biobank sustainability. Biopreservation and biobanking 2014; 12(1): 60-68. [DOI:10.1089/bio.2013.0064]
39. Longtin R. Canadian province seeks control of its genes. Journal of the national cancer institute 2004; 96(21): 1567-1569. [DOI:10.1093/jnci/96.21.1567]
40. Winickoff DE. Genome and nation: iceland's health sector database and its legacy. Innovations technology, governance, globalization 2006; 1(2): 80-105. [DOI:10.1162/itgg.2006.1.2.80]
41. Yuille M, van Ommen GJ, Bréchot C, Cambon-Thomsen A, Dagher G, Landegren U, Litton JE, Pasterk M, Peltonen L, Taussig M, Wichmann HE, Zatloukal K. Biobanking for Europe. Briefings in bioinformatics 2008; 9(1): 14-24. [DOI:10.1093/bib/bbm050]
42. Turner A, Dallaire-Fortier C, Murtagh MJ. Biobank Economics and the "Commercialization Problem". Spontaneous generations: journal for the history and philosophy of science 2013; 7(1): 69-80. [DOI:10.4245/sponge.v7i1.19555]
43. Webster A, Martin P, Lewis G, Smart A. Integrating pharmacogenetics into society: in search of a model. Nature reviews genetics 2004; 5(9): 663-669. [DOI:10.1038/nrg1430]
44. Patil S, Majumdar B, Awan KH, Sarode GS, Sarode SC, Gadbail AR, Gondivkar S. Cancer oriented biobanks: A comprehensive review. Oncology reviews 2018; 12(1): 357. [DOI:10.4081/oncol.2018.357]
45. Van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S. Assessing researcher needs for a virtual biobank. Biopreservation and biobanking 2017; 15(3): 203-210. [DOI:10.1089/bio.2016.0009]
46. Asslaber M, Abuja PM, Stark K, Eder J, Gottweis H, Trauner M, Samonigg H, Mischinger HJ, Schippinger W, Berghold A, Denk H, Zatloukal K. The genome austria tissue bank (gatib). Pathobiology 2007; 74(4): 251-258. [DOI:10.1159/000104453]
47. Es HA, Montazeri L, Aref AR, Vosough M, Baharvand HJTib. Personalized cancer medicine: an organoid approach. Trends in biotechnol 2018; 36(4): 358-371. [DOI:10.1016/j.tibtech.2017.12.005]
48. van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor-Weiner A, Kester L, JC, McLaren-Douglas A, Blokker J, Jaksani S, Bartfeld S, Volckman R, van Sluis P, Li VS, Seepo S, Sekhar Pedamallu C, Cibulskis K, Carter SL, McKenna A, Lawrence MS, Lichtenstein L, Stewart C, Koster J, Versteeg R, van Oudenaarden A, Saez-Rodriguez J, Vries RG, Getz G, Wessels L, Stratton MR, McDermott U, Meyerson M, Garnett MJ, Clevers H. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015; 161(4): 933-945. [DOI:10.1016/j.cell.2015.03.053]
49. Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H, Korving J, van Boxtel R, Duarte AA, Lelieveld D, van Hoeck A, Ernst RF, Blokzijl F, Nijman IJ, Hoogstraat M, van de Ven M, Egan DA, Zinzalla V, Moll J, Boj SF, Voest EE, Wessels L, van Diest PJ, Rottenberg S, Vries RGJ, Cuppen E, Clevers H. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 2018; 172(1-2): 373-386. [DOI:10.1016/j.cell.2017.11.010]
50. Kaye J, Whitley EA, Lund D, Morrison M, Teare H, Melham K. Dynamic consent: a patient interface for twenty-first century research networks. European journal of human genetics 2015; 23(2): 141-146. [DOI:10.1038/ejhg.2014.71]
51. Saadat S, Yousefifard M, Asady H, Jafari AM, Fayaz M, Hosseini M. The most important causes of death in Iranian population; a retrospective cohort study. Emergency 2015; 3(1): 16-21.
52. Rudan I, Marušić A, Campbell H. Developing biobanks in developing countries. Journal of global health 2011; 1(1): 2-4.
53. Mohammadi M. Biobanking in the developing world; maximum specimens, minimum infrastructure. Basic and clinical cancer research 2017; 9(4): 1-3.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |